A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

This study is testing a combination of three drugs — tagraxofusp, azacitidine, and venetoclax — in adults with acute myeloid leukemia (AML) who are in remission but still have very small amounts of detectable cancer cells (called measurable residual disease, or MRD). **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of AML - You are in remission (complete or near-complete) with less than 5% cancer cells in your bone marrow - Your cancer cells test positive for a marker called CD123 - Residual disease is still detectable at 0.1% or more by specialized testing - Your heart, liver, and kidney function are adequate **You may NOT be eligible if...** - You are not in remission - You have significant organ dysfunction - Your cancer cells do not have the CD123 marker Talk to your doctor to see if this trial is right for you.